131 related articles for article (PubMed ID: 25130857)
1. Carbohydrate malabsorption mechanism for tumor formation in rats treated with the SGLT2 inhibitor canagliflozin.
Mamidi RN; Proctor J; De Jonghe S; Feyen B; Moesen E; Vinken P; Ma JY; Bryant S; Snook S; Louden C; Lammens G; Ways K; Kelley MF; Johnson MD
Chem Biol Interact; 2014 Sep; 221():109-18. PubMed ID: 25130857
[TBL] [Abstract][Full Text] [Related]
2. Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin.
De Jonghe S; Proctor J; Vinken P; Feyen B; Wynant I; Marien D; Geys H; Mamidi RN; Johnson MD
Chem Biol Interact; 2014 Dec; 224():1-12. PubMed ID: 25289773
[TBL] [Abstract][Full Text] [Related]
3. Renal tubular and adrenal medullary tumors in the 2-year rat study with canagliflozin confirmed to be secondary to carbohydrate (glucose) malabsorption in the 15-month mechanistic rat study.
De Jonghe S; Johnson MD; Mamidi RNVS; Vinken P; Feyen B; Lammens G; Proctor J
Chem Biol Interact; 2017 Nov; 277():85-90. PubMed ID: 28916336
[TBL] [Abstract][Full Text] [Related]
4. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects.
Sha S; Devineni D; Ghosh A; Polidori D; Chien S; Wexler D; Shalayda K; Demarest K; Rothenberg P
Diabetes Obes Metab; 2011 Jul; 13(7):669-72. PubMed ID: 21457428
[TBL] [Abstract][Full Text] [Related]
5. Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Nomura S; Sakamaki S; Hongu M; Kawanishi E; Koga Y; Sakamoto T; Yamamoto Y; Ueta K; Kimata H; Nakayama K; Tsuda-Tsukimoto M
J Med Chem; 2010 Sep; 53(17):6355-60. PubMed ID: 20690635
[TBL] [Abstract][Full Text] [Related]
6. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
Nicolle LE; Capuano G; Ways K; Usiskin K
Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
[TBL] [Abstract][Full Text] [Related]
7. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, for the management of type 2 diabetes.
Brunton S; Reid TS
Hosp Pract (1995); 2014 Aug; 42(3):96-108. PubMed ID: 25255411
[TBL] [Abstract][Full Text] [Related]
8. Successful integration of nonclinical and clinical findings in interpreting the clinical relevance of rodent neoplasia with a new chemical entity.
Ways K; Johnson MD; Mamidi RN; Proctor J; De Jonghe S; Louden C
Toxicol Pathol; 2015 Jan; 43(1):48-56. PubMed ID: 25398756
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus.
Devineni D; Curtin CR; Polidori D; Gutierrez MJ; Murphy J; Rusch S; Rothenberg PL
J Clin Pharmacol; 2013 Jun; 53(6):601-10. PubMed ID: 23670707
[TBL] [Abstract][Full Text] [Related]
10. Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial.
Stein P; Berg JK; Morrow L; Polidori D; Artis E; Rusch S; Vaccaro N; Devineni D
Metabolism; 2014 Oct; 63(10):1296-303. PubMed ID: 25110280
[TBL] [Abstract][Full Text] [Related]
11. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats.
Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
J Pharm Pharmacol; 2014 Jul; 66(7):975-87. PubMed ID: 24533859
[TBL] [Abstract][Full Text] [Related]
12. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.
Devineni D; Morrow L; Hompesch M; Skee D; Vandebosch A; Murphy J; Ways K; Schwartz S
Diabetes Obes Metab; 2012 Jun; 14(6):539-45. PubMed ID: 22226086
[TBL] [Abstract][Full Text] [Related]
13. Effects of hydrochlorothiazide on the pharmacokinetics, pharmacodynamics, and tolerability of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in healthy participants.
Devineni D; Vaccaro N; Polidori D; Rusch S; Wajs E
Clin Ther; 2014 May; 36(5):698-710. PubMed ID: 24726680
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Nyirjesy P; Zhao Y; Ways K; Usiskin K
Curr Med Res Opin; 2012 Jul; 28(7):1173-8. PubMed ID: 22632452
[TBL] [Abstract][Full Text] [Related]
15. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
16. C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors.
Koga Y; Sakamaki S; Hongu M; Kawanishi E; Sakamoto T; Yamamoto Y; Kimata H; Nakayama K; Kuriyama C; Matsushita Y; Ueta K; Tsuda-Tsukimoto M; Nomura S
Bioorg Med Chem; 2013 Sep; 21(17):5561-72. PubMed ID: 23809172
[TBL] [Abstract][Full Text] [Related]
17. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
[TBL] [Abstract][Full Text] [Related]
18. Treating type 2 diabetes with canagliflozin.
Van Gilder D; Jungemann S
S D Med; 2013 Jul; 66(7):280-1. PubMed ID: 23957114
[No Abstract] [Full Text] [Related]
19. Metabolism and excretion of canagliflozin in mice, rats, dogs, and humans.
Mamidi RN; Cuyckens F; Chen J; Scheers E; Kalamaridis D; Lin R; Silva J; Sha S; Evans DC; Kelley MF; Devineni D; Johnson MD; Lim HK
Drug Metab Dispos; 2014 May; 42(5):903-16. PubMed ID: 24568888
[TBL] [Abstract][Full Text] [Related]
20. Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2.
Ellsworth BA; Meng W; Patel M; Girotra RN; Wu G; Sher PM; Hagan DL; Obermeier MT; Humphreys WG; Robertson JG; Wang A; Han S; Waldron TL; Morgan NN; Whaley JM; Washburn WN
Bioorg Med Chem Lett; 2008 Sep; 18(17):4770-3. PubMed ID: 18707880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
